Research output per year
Research output per year
Personal profile
Expertises
Crohn’s disease; ulcerative colitis; biologic therapy; Good Clinical Practice (GCP); experience in preparing and running a multicenter clinical study.
Main research areas
Optimizing infliximab therapy in patients with inflammatory bowel disease.
Current research
An investigator-initiated double-blind, randomized, placebo controlled, multicentre clinical trial with the aim to investigate if infliximab can safely and favourably be discontinued in patients with Crohn's disease, in sustained complete remission on infliximab maintenance therapy.
Potential conflicts of interest
Served as speaker for Janssen
Fingerprint
Dive into the research topics where Sine Schnoor Buhl is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Research output
- 11 Journal article
-
A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patients' and physicians' preferences and adherence
Christensen, K. R., Steenholdt, C., Buhl, S., Brynskov, J. & Ainsworth, M. A., 4 Mar 2022, In: Scandinavian Journal of Gastroenterology. 57, 3, p. 274-281 8 p.Research output: Contribution to journal › Journal article › Research › peer-review
3 Citations (Scopus) -
Discontinuation of Infliximab Therapy in Patients with Crohn’s Disease
Sine, B., Casper, S., Jørn, B., Risager, C. K., Maria, D-R., Østergaard, T. O., Klaus, B., Wirenfeldt, K. T., Frederik, D. J., Niels, T., Jørgen, J., Akbar, M., Natalia, P., Jens, K., Sven, A., Efsen, D. E., Ida, V., Gerhardt, C. A., Jan, M., Taina, S., & 7 others, 14 Jun 2022, In: NEJM Evidence. 1, 8, p. EVIDoa2200061Research output: Contribution to journal › Journal article › Research › peer-review
-
Drug Levels Associated with Optimal Discrimination Between Remission and Non-Remission and Comparison of Antibody Assays During First Year of Stable Infliximab Maintenance Therapy in Inflammatory Bowel Disease
Dorn-Rasmussen, M., Buhl, S., Brynskov, J., Bay, J. T., Bolstad, N., Klausen, T. W., Warren, D. J., Ainsworth, M. A. & Steenholdt, C., 1 Apr 2022, In: Therapeutic Drug Monitoring. 44, 2, p. 290-300 11 p.Research output: Contribution to journal › Journal article › Research › peer-review
-
Fatigue is a systemic extraintestinal disease manifestation largely independent of disease activity, chronicity, and nutritional deficiencies in inflammatory bowel disease on biologics
Christensen, K. R., Ainsworth, M. A., Steenholdt, C., Buhl, S., Skougaard, M., Brynskov, J., Jørgensen, T. S. & Kristensen, L. E., Sep 2022, In: Scandinavian Journal of Gastroenterology. 57, 9, p. 1051-1057 7 p.Research output: Contribution to journal › Journal article › Research › peer-review
-
Identifying and understanding disease burden in patients with inflammatory bowel disease
Christensen, K. R., Ainsworth, M. A., Skougaard, M., Steenholdt, C., Buhl, S., Brynskov, J., Kristensen, L. E. & Jørgensen, T. S., Oct 2022, In: BMJ Open Gastroenterology. 9, 1, 000994.Research output: Contribution to journal › Journal article › Research › peer-review